Clinical trial
Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.
NCT00469560 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2007
- Completion date
- November 30, 2013
- Enrollment
- 158 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.